Volume | 3,313,229 |
|
|||||
News | (3) | ||||||
Day High | 1.6399 | Low High |
|||||
Day Low | 1.30 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Veru Inc | VERU | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.41 | 1.30 | 1.6399 | 1.43 | 1.63 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
10,769 | 3,313,229 | $ 1.48 | $ 4,896,335 | - | 0.36 - 1.92 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:06 | 95 | $ 1.45 | USD |
Veru Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
207.86M | 146.38M | - | 16.3M | -93.09M | -0.64 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Veru News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VERU Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.38 | 1.75 | 1.30 | 1.60 | 2,871,330 | 0.07 | 5.07% |
1 Month | 1.14 | 1.92 | 1.00 | 1.51 | 3,922,085 | 0.31 | 27.19% |
3 Months | 0.385 | 1.92 | 0.370001 | 1.13 | 2,538,690 | 1.07 | 276.62% |
6 Months | 1.02 | 1.92 | 0.36 | 0.9094801 | 2,096,019 | 0.43 | 42.16% |
1 Year | 1.34 | 1.92 | 0.36 | 0.9702647 | 1,634,041 | 0.11 | 8.21% |
3 Years | 7.85 | 24.55 | 0.36 | 10.34 | 4,378,945 | -6.40 | -81.53% |
5 Years | 1.55 | 24.56 | 0.36 | 10.19 | 3,262,297 | -0.10 | -6.45% |
Veru Description
Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility, and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Sexual health business and Research & development. Some of its products include Zuclomiphene, Veru-111, Veru-100, FC2, and Roman Swipes. The company generates the majority of its revenue from the United States. |